Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery

The Effects of Atorvastatin on the Occurrence of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00611143

Enrollment

124

Registered

2008-02-08

Start date

2006-05-31

Completion date

2007-05-31

Last updated

2008-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass

Keywords

Off-pump coronary artery bypass graft, Atorvastatin, Postoperative atrial fibrillation

Brief summary

The purpose of this study is to determine whether pretreatment with atorvastatin protects against atrial fibrillation following off-pump coronary artery bypass graft surgery.

Detailed description

Atrial fibrillation after cardiac surgery is the most common arrhythmic complication that may increase incidence of congestive heart failure, renal insufficiency, and stroke, which increase the length of hospital stay, the rates of re-hospitalization, and cost of care. Its pathogenesis is multifactorial, and its prevention and management remain suboptimal. Recently, observational evidence has suggested that patients who have undergone previous statin therapy have a lower incidence of postoperative atrial fibrillation. The purpose of this study is to determine whether pretreatment with atorvastatin protects against atrial fibrillation following off-pump coronary artery bypass graft surgery.

Interventions

DRUGatorvastatin

atorvastatin 20 mg/d, started 3 days before surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* consecutive patients scheduled for the elective off-pump CABG surgery

Exclusion criteria

* prior statin use * previous episodes of atrial fibrillation * impaired renal function with serum creatinine \>2mg/dL * serum aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal * a malignancy or inflammatory disease

Design outcomes

Primary

Measure	Time frame
the development of postoperative in-hospital atrial fibrillation confirmed by 12-lead ECG	in-hospital period

Secondary

Measure	Time frame
major adverse cardiac and cerebrovascular events rate, including cardiovascular death, postoperative stroke, myocardial infarction, or persistent atrial fibrillation,and identification of predictive markers for postoperative atrial fibrillation	30 days

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026